Nanobiotix Shares Soar by 4.5%, Leading the SBF 120
The French biotech company marks a new surge in early afternoon, taking the lead in the broad Paris index. The stock has moved back above its short-term moving averages after a week of consolidation. Its annual performance remains extraordinary.
A Rebound That Places the Stock Above Its Short-Term Moving Averages
Nanobiotix shares gain 4.25% to €34.36, marking the highest rise in the SBF 120 as the broad index advances by 0.49%. This movement brings the stock above its MM20 (€33.06, a gap of +3.93%) and MM50 (€33.96, +1.18%), two thresholds that the stock had briefly dropped below in previous sessions. The gap with the MM200 at €24.95 now reaches +37.72%, reflecting the rally that has been ongoing for a year. The RSI at 47 remains neutral, which leaves room for progression before entering an overbought zone.
The next identified threshold is the resistance at €36.20, about 5% from the current price. The session comes after a decline of 3.38% over the past week, marked by profit-taking on a stock that still shows +657.7% over a year and +19.72% over three months. Today's rebound mitigates the weekly decline without completely erasing it.
An Extraordinary Annual Performance Driven by Clinical Dynamics
The valuation of the biotech is supported by the clinical advances of the candidate JNJ-1900 (NBTXR3), identified as a key opportunity during the first quarter 2026 publication (June 2, 2026), alongside the strengthening of the Nanoprimer platform. The risks mentioned on that occasion related to the limited progress of the current standard of care in inoperable non-small cell lung cancer as well as potential protocol analysis hazards. By the end of June, the company had also bolstered its cash reserves and published encouraging preliminary results in phase 2, a sequence that fueled the summer rally.
The stock remains listed in Paris (NANO) and on the Nasdaq (ADS NBTX) with a 1 for 1 ratio, maintaining balanced liquidity between the two venues. Both lines are strongly correlated on the same day. In the short term, the resistance zone at €36.20 is the next technical level identified in the data.
